Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices

NCT02856646•Bristol-Myers Squibb

Summary

The purpose of this study is to gather data on patients diagnosed with and treated for classical Hodgkin Lymphoma (cHL). It aims to closely observe how treatment for cHL is rendered, as well as assess the outcome of those treatment options and their impact on quality of life. Additional analyses will also attempt to identify prognostic or predictive biomarkers

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com
•Histologically confirmed diagnosis of Classical Hodgkin Lymphoma (cHL)
•Patients who are treatment-naïve, or are within ± 2 weeks beginning any line of therapy at time of enrollment
•Patients must be within ± 2 weeks of Day 1 of the first cycle of any line of therapy to enroll; a cycle is practice-defined for chemotherapy, targeted therapy, or immunotherapy-based regimens.
•Any Eastern Cooperative Oncology Group (ECOG) or Karnofsky performance status (PS)
•Patients must have available medical records for the date of diagnosis of cHL and available medical records documenting any prior treatment and treatment dates for the Hodgkin lymphoma, including chemotherapy, radiation, surgery and other anti-cancer therapy received.
•Patients must consent for use of their FFPE tissue blocks for exploratory analyses

Exclusion Criteria

•Patients with unknown date of diagnosis of cHL
•Patients whose prior cHL therapy, and dates of therapy (eg, surgery, radiation, or drug therapy) are unknown
•Any other non-HL (non-Hodgkin Lymphoma) active malignancy for which the patient is receiving treatment
•Patients participating in a clinical study that does not allow enrollment into a non-interventional study
•Patients enrolled who go on to receive only supportive, palliative, hospice, or end-of-life care remain on study and should not be discontinued from follow-up.

Locations (1)

Norton Cancer Institute

Louisville, Kentucky, United States

Key Dates

Start Date

October 7, 2016

Primary Completion Date

September 30, 2020

Completion Date

September 30, 2020

Last Updated

December 15, 2021

Enrollment

290

ACTUAL participants

Conditions

Hodgkin's Disease

Isatuximab During Stem Cell Collection and Transplant in Patients With Multiple Myeloma and Lymphoma

NCT05346809

LymphomaMultiple Myeloma+2 more

View study

RECRUITINGPHASE2/PHASE3

Treatment Strategy for Relapsed/Refractory Hodgkin Lymphoma

NCT05595447

Hodgkin LymphomaRefractory Hodgkin Lymphoma+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 15, 2021Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices

Inclusion Criteria

Exclusion Criteria

Isatuximab During Stem Cell Collection and Transplant in Patients With Multiple Myeloma and Lymphoma

Treatment Strategy for Relapsed/Refractory Hodgkin Lymphoma

Autologous/Allogeneic TGFbeta-resistant LMP-specific CTL, Lymphoma (TGF-beta)

Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies

An Investigational Immuno-therapy Safety and Effectiveness Study of Nivolumab in Combination With Brentuximab Vedotin to Treat Non-Hodgkin Lymphomas

A Study to Evaluate the Safety, Pharmacokinetics, and Hematopoietic Stem Cell Mobilization of TG-0054 Alone or in Combination With G-CSF in Patients With Multiple Myeloma, Non-Hodgkin Lymphoma or Hodgkin Disease